|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
Juno and the FDA screwed up. People died. What now? [EndPoints]
|
|
|
|
|
|
I’m
not saying that top Juno execs or FDA officials were duplicitous or
didn’t believe that they were right. That would be a crime. But they
were clearly wrong, and Juno recklessly jumped back into human testing
without being required by regulators to prove their case and make the
proper adjustments.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
J&J approaches $20B-valued Actelion about takeover deal [FierceBiotech]
|
|
|
|
|
|
The
products, pulmonary arterial hypertension drugs Opsumit and Uptravi,
have both made solid starts to commercial life, cementing expectations
that their annual sales will top out at approximately $2 billion. That
would give J&J a ready-made source of revenues at a time when it is
looking to M&A to offset the forecast effect of biosimilars on its
blockbuster Remicade.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Workshop: measuring the impact of pharmacovigilance activities [EMA]
|
|
|
|
|
|
This
workshop will bring together the expertise from international partners
and stakeholders who participate in pharmacovigilance activities:
regulatory and public health bodies, healthcare-professional and
patient/consumer organisations, academia, learned societies and the
pharmaceutical industry.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
5.8.1 ASH - Communiqués
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
Republicans reach deal to pass Cures Act by end of year, but Democrats pushing for changes [STAT]
|
|
|
|
|
|
The
Cures Act, which passed the House by a landslide in July 2015, has been
the focus of dozens of congressional hearings and endless debate among
Republicans and Democrats over the past three years. During this time,
more than 1,300 lobbyists have roamed the halls of Congress, pressing
for passage on behalf of pharmaceutical companies, medical device firms,
and patient advocacy groups.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
|
What Not to Say to a Cancer Patient [NY Times]
|
|
|
|
|
|
“I
was dealing with the possibility that my life would end shortly, or if
it didn’t, it would be changed dramatically. False optimism devalued
what was going on in my body. People were insensitive not from a lack of
compassion but from not knowing what is really helpful.”
|
|
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.8 Communication
|
|
|